Loading…

Loading grant details…

Completed HORIZON European Commission

The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)

€11.56M EUR

Funder European Commission
Recipient Organization Carmat
Country France
Start Date Oct 01, 2022
End Date Jun 30, 2025
Duration 1,003 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190185733
Grant Description

At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure.

Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The device is electro-hydraulically driven with a shape close to that of a human heart.

Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body.Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility.

With Aeson®, Carmat is creating a new therapeutic class of “physiologic heart replacement therapy” (PHRT).

All Grantees

Carmat

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant